both uptake mechanisms are non-competitively inhibited by the potential antiparkinson drugs 1-aminoadamantane ( amantadine , d 1 : ki1 = 57 microm , ki2 = 96 microm ) and 1-amino-3,5-dimethyladamantane ( memantine , d 145 : ki1 = 97 microm , ki2 = 150 microm ) .
C0002403
amantadine
C0025242
memantine